PUBLICATIONS

2023

Andrew J Kerr; Yeunhyang Choi; Michael JA Williams; Ralph AH Stewart; Harvey D White; Gerry Devlin; Vanessa Selak; Mildred Ai Wei Lee; Seif El-Jack; Philip D Adamson; Sarah Fairley; Rodney T Jackson; Katrina Poppe

Paired risk scores to predict ischaemic and bleeding risk twenty-eight days to one year after an acute coronary syndrome‍‍

‍Robert J. Mentz, M.D; Jyotsna Garg, M.S; Frank W. Rockhold, Ph.D;Javed Butler, M.D, M.P.H, M.B.A; Carmine G. De Pasquale, B.M, B.S; Justin A.Ezekowitz, M.B, B.Ch; Gregory D. Lewis, M.D; Eileen O’Meara, M.D; PiotrPonikowski, M.D, Richard W. Troughton, M.B, Ch.B; Yee Weng Wong, M.B, B.S;Lilin She, Ph.D; Josephine Harrington, M.D; Robert Adamczyk, Pharm.D; NicoleBlackman, Ph.D; and Adrian F. Hernandez, M.D, M.H.S; for the HEART-FID Investigators*

Ferric Carboxymaltose in Heart Failure with Iron Deficiency‍

Dan D. Nguyen, MD; John A. Spertus, MD, MPH; Karen P. Alexander, MD; Jonathan D. Newman, MD; John A. Dodson, MD, MPH; Philip G. Jones, MS; Susanna R. Stevens, MS; Sean M. O’Brien, PHD; Reto Gamma,MBBS; Gian P. Perna, MD; Pallav Garg, MBBS, MSC; João V. Vitola, MD, PHD; Benjamin J.W. Chow, MD; Andras Vertes, MD; Harvey D. White, MB CHB, DSC; Paola E.P. Smanio, MD, PHD; Roxy Senior, MD, DM; Claes Held, MD, PHD; Jianghao Li, PHD; William E. Boden, MD; Daniel B. Mark, MD, MPH; Harmony R. Reynolds, MD;
Sripal Bangalore, MD, MHA; Paul S. Chan, MD, MSC; Gregg W. Stone, MD; Suzanne V. Arnold, MD, MHA; David J. Maron, MD; Judith S. Hochman, MD; on behalf of the ISCHEMIA Research Group

‍Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease‍

Gregg W. Stone, MD; Ziad A. Ali, MD, DPHIL; Sean M. O’Brien, PHD; Grace Rhodes, MS; Philippe Genereux, MD; Sripal Bangalore, MD, MHA; Kreton Mavromatis, MD; Jennifer Horst,MS; Ovidiu Dressler, MD; Kian Keong Poh, MD; Ranjit K. Nath, MD; NagarajaMoorthy, MD; Adam Witkowski, MD; Sudhanshu K. Dwivedi, MD; Olga Bockeria, MD; JiyanChen, MD; Paola E.P. Smanio, MD; Michael H. Picard, MD; Bernard R. Chaitman, MD;Daniel S. Berman, MD; Leslee J. Shaw, PHD; William E. Boden, MD; Harvey D.White, MB, CHB; Stephen E. Fremes, MD; Yves Rosenberg, MD, MPH; Harmony R.Reynolds, MD; John A. Spertus, MD, MPH; Judith S. Hochman, MD; David J. Maron,MD; on behalf of the ISCHEMIA Research Group

‍Impact of Complete Revascularization in the ISCHEMIA Trial

Jacques Genest

Transient very low LDL-C levels: a legacy effect for cardiovascular prevention?

‍This editorial refers to ‘Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial’, byG.G. Schwartz et al.‍

GregoryG. Schwartz; Michael Szarek; Deepak L. Bhatt; Vera A. Bittner; MajaBujas-Bobanovic; Rafael Diaz; Sergio Fazio; Zlatko Fras; Shaun G. Goodman; RobertA. Harrington; J. Wouter Jukema; Garen Manvelian; Robert Pordy; Kausik K. Ray; Michel Scemama; HarveyD. White; Ph. Gabriel Steg for the ODYSSEY OUTCOMES Investigators

‍Transiently achieved very low low-density lipoprotein cholesterol levels by statin andalirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial‍

‍Natalie C. Ward, PhD; Gerald F. Watts, DSc, PhD, DM; Warrick Bishop, MBBS, David Colquhoun, MBBS; Christian Hamilton-Craig, MBBS; David L. Hare, MBBS, DPM; Nadarajah Kangaharan, MD; Karam M. Kostner, MD, PhD; Leonard Kritharides, MBBS, Ph; Richard O’Brien, MBBS, PhD; Trevor A. Mori, PhD; Paul J. Nestel, MD; Stephen J. Nicholls, MBBS; PhD; Peter J.Psaltis, MBBS, PhD; Natalie Raffoul, BPharm (Hons), MHM; Harvey D. White, DSc; David R. Sullivan, MBBS

Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations ‍

‍Judith S. Hochman, MD; Rebecca Anthopolos, DrPH; Harmony R. Reynolds, MD; Sripal Bangalore, MD, MHA; Yifan Xu, MPH; Sean M. O’Brien, PhD; Stavroula Mavromichalis, MS; Michelle Chang, MPH; Aira Contreras, MA; Yves Rosenberg, MD, MPH; Ruth Kirby, ASN; Balram Bhargava, MD, DM; Roxy Senior, MD, DM; Ann Banfield, RGN, BSc; Shaun G. Goodman, MD, MSc; Renato D. Lopes, MD, MHS, PhD; Radosław Pracoń, MD, PhD; Jose Lopez-Sendon, MD; Aldo Pietro Maggioni, MD; Jonathan D. Newman, MD, MPH; Jeffrey S. Berger, MD; Mandeep S. Sidhu, MD; Harvey D. White, DSc; Andrea B. Troxel, ScD; Robert A. Harrington, MD; William E. Boden, MD; Gregg W. Stone, MD; Daniel B. Mark, MD, MPH; John A. Spertus, MD, MPH; David J. Maron, MD; on behalf of the ISCHEMIA-EXTEND Research Group*
‍
Survival After Invasive or Conservative Management of Stable Coronary Disease

2022-2019

Patrick M. Moriarty MD, Philippe Gabriel Steg MD, Jennifer McGinniss PhD, Andreas M. Zeiher MD, Harvey D. White DSc, Garen Manvelian MD, Robert Pordy MD, Megan Loy BAppSc, J. Wouter Jukema MD, PhD, Robert A. Harrington MD, Jessica V. Gray BS, Lauryn K. Gorby BS, Shaun G. Goodman MD, MSc ,Rafael Diaz MD , Vera A. Bittner MD, MSPH ,Deepak L. Bhatt MD, MPH , Michael Szarek PhD ,Gregory G. Schwartz MD, PhD, for the ODYSSEY OUTCOMES Investigators
‍
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes

Kristina Lambrakis, John K. French, Ian A. Scott, Tom Briffa, David Brieger, Michael E. Farkouh, Harvey White, Anthony (Ming-Yu) Chuang, Kathryn Tiver, Stephen Quinn, Billingsley Kaambwa, Matthew Horsfall, Erin Morton, and Derek P Chew
‍
The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design

Jean-Claude Tardif, Marc A. Pfeffer, Simon Kouz, Wolfgang Koenig, Aldo P. Maggioni, John J.V.McMurray, VincentMooser, DavidD.Waters, Jean C. Grégoire1, Philippe L. L’Allier1, Wouter J. Jukema, Harvey D. White, ThereseHeinonen, Donald M. Black, Fouzia Laghrissi-Thode, Sylvie Levesque, Marie-Claude Guertin, and Marie-Pierre Dubé, for the dal-GenE Investigators
‍
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial

Patrick M. Moriarty MD, Philippe Gabriel Steg MD, Jennifer McGinniss PhD, Andreas M. Zeiher MD, Harvey D. White DSc, Garen Manvelian MD, Robert Pordy MD, Megan Loy BAppSc, J. Wouter Jukema MD, PhD, Robert A. Harrington MD, Jessica V. Gray BS, Lauryn K. Gorby BS, Shaun G. Goodman MD, MSc, Rafael Diaz MD, Vera A. Bittner MD, MSPH, Deepak L. Bhatt MD, MPH, Michael Szarek PhD, Gregory G. Schwartz MD, PhD, for the ODYSSEY OUTCOMES Investigators
‍
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes

Ralph A. H. Stewart, MD; Adrienne Kirby, MSc; Harvey D. White, DSc; Simone L. Marschner, MSc; Malcolm West, PhD; Peter L. Thompson, MD, FRACP; David Sullivan, MD; Edward Janus, MD, PhD; David Hunt, MD; Leonard Kritharides, PhD; Anthony Keech, MD; John Simes, MD; Andrew M. Tonkin, MD.

ORIGINAL RESEARCH B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients With Coronary Heart Disease

Anda Bularga, MD*; John Hung, MD*; Marwa Daghem, MD; Stacey Stewart, MSc; Caelan Taggart , MD; Ryan Wereski, MD;Trisha Singh, MD; Mohammed N. Meah , MD; Takeshi Fujisawa , PhD; Amy V. Ferry, PhD; Justin Chiong, MD;William S. Jenkins, MD; Fiona E. Strachan, PhD; Scott Semple, PhD; Edwin J.R. van Beek , PhD; Michelle Williams , MD;Damini Dey , PhD; Chris Tuck , BSc; Andrew H. Baker , PhD; David E. Newby , MD; Marc R. Dweck , MD;Nicholas L. Mills , MD; Andrew R. Chapman , MD
‍
Coronary Artery and Cardiac Disease in Patients With Type 2 Myocardial Infarction: A Prospective Cohort Study

Harvey D. White , DSc
‍
Zooming in on the Enigmas of Type 2 Myocardial Infarction

Renato D. Lopes, Patricia O. Guimaraes, Gregory G. Schwartz, Deepak L. Bhatt, Vera A. Bittner, Andrzej Budaj, Anthony J. Dalby, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Robert Gabor Kiss, Megan Loy, Robert Pordy, Yann Poulouin, Michael Szarek, Harvey D. White, Philippe Gabriel Steg for the ODYSSEY OUTCOMES Investigators
‍
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial

Sean Tan, Harvey D. White and Jamie Layland
‍
Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?

Petr Ostadal, Philippe Gabriel Steg, Yann Poulouin, Deepak L Bhatt, Vera A Bittner, Terrence Chua, Rafael Diaz, Shaun G Goodman, Yong Huo,Johan Wouter Jukema, Yuri Karpov, Robert Pordy, Michel Scemama, Michael Szarek, Harvey D White, Gregory G Schwartz, for the ODYSSEYOUTCOMES Investigators*
‍
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Rifly Rafiudeen, Peter Barlis, Harvey D White and William van Gaal
‍
Type 2 MI and Myocardial Injury in the Era ofHigh-sensitivity Troponin

MalcolmWest, PhD; Adrienne Kirby, MSc; Ralph A. Stewart, MD; Stefan Blankenberg, MD;David Sullivan, MD; Harvey D. White, DSc; David Hunt, MD; Ian Marschner, PhD;Edward Janus, PhD; Leonard Kritharides , PhD; Gerald F. Watts, DSc; John Simes, MD; Andrew M. Tonkin , MD; on behalf of the LIPID Study Group*
‍
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable CoronaryHeart Disease: The LIPID Study

Claes Held, MD, PhD; Nermin Hadziosmanovic, MSc; Philip E. Aylward, BM BCh, PhD; Emil Hagstrom, MD, PhD; Judith S. Hochman, MD; Ralph A. H. Stewart, MD; Harvey D.White, MBChB, DSc; Lars Wallentin, MD, PhD
‍
Body Mass Index and Association With Cardiovascular Outcomes in Patients With StableCoronary Heart Disease –A STABILITY Substudy

P.J. Devereaux, A. Lamy, M.T.V. Chan, R.V. Allard, V.V. Lomivorotov, G. Landoni, H. Zheng, D. Paparella, M.H. McGillion, E.P. Belley-Cote,J.L. Parlow, M.J. Underwood, C.Y. Wang, N. Dvirnik, M. Abubakirov, E.Fominskiy, S. Choi, S. Fremes, F. Monaco, G. Urrutia, M. Maestre, L.A. Hajjar,G.S. Hillis, N.L. Mills, V. Margari, J.D. Mills, J.S. Billing, E. Methangkool,C.A. Polanczyk, R. Sant’Anna, D. Shukevich, D. Conen, P.A. Kavsak, M.J.McQueen, K. Brady, J. Spence, Y. Le Manach,* R. Mian, S.F. Lee, S.I.Bangdiwala, S. Hussain, F.K. Borges, S. Pettit, J. Vincent, G.H. Guyatt, S.Yusuf, J.S. Alpert, H.D. White, and R.P. Whitlock, for the VISION CardiacSurgery Investigators
‍
High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality

Supplement to: Devereaux PJ, Lamy A, Chan MTV, et al.
‍
High-sensitivity troponin I after cardiac surgery and 30-day mortality. N Engl J Med2022;386:827-36. DOI: 10.1056/NEJMoa2000803

Benjamin E. Peterson, MD, MPH;Robert A. Harrington, MD; Gregg W. Stone, MD, PhD; Ph. Gabriel Steg , MD; C.Michael Gibson, MD, MS; Christian W. Hamm, MD; Matthew J. Price, MD; Renato D.Lopes , MD, MHS, PhD; Sergio Leonardi , MD; Jayne Prats , PhD; Efthymios N.Deliargyris , MD; Kenneth W. Mahaffey, MD;Harvey D. White, DSc; Deepak L. Bhatt, MD, MPH
‍
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

Matthew A. Cavender , MD, MPH; Robert A. Harrington, MD; Gregg W. Stone , MD; Ph. Gabriel Steg , MD; C. Michael Gibson, MD; Christian W. Hamm, MD; Matthew J. Price , MD; Renato D. Lopes , MD; Sergio Leonardi , MD; Efthymios N. Deliargyris , MD; Jayne Prats , PhD; Kenneth W. Mahaffey, MD; Harvey D. White , DSc; Deepak L. Bhatt , MD, MPH; on behalf of the CHAMPION PHOENIX Investigators*

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

Claes Held , MD, PhD; Nermin Hadziosmanovic, MSc; Philip E. Aylward, BM BCh, PhD; Emil Hagstrom, MD, PhD; Judith S. Hochman , MD; Ralph A. H. Stewart, MD; Harvey D. White , MBChB, DSc; Lars Wallentin, MD, PhD

‍Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease –A STABILITY Substudy ‍‍

Eliano P. Navarese, and Felicita Andreotti

‍Cardiacmortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes. ‍‍

Harvey D.White
‍
Cardiac death should be the primary endpoint for revascularization trials and meta-analyses

Jose L. Lopez-Sendon, Derek D. Cyr, Daniel B. Mark, Sripal Bangalore, Zhen Huang, Harvey D. White, Karen P. Alexander, Jianghao Li,
Rajesh Goplan Nair, Marcin Demkow, Jesus Peteiro, Gurpreet S.Wander, Elena A. Demchenko, Reto Gamma, Milind Gadkari, Kian Keong Poh, Thuraia Nageh, Peter H. Stone, Matyas Keltai, Mandeep Sidhu, Jonathan D. Newman, William E. Boden, Harmony R. Reynolds, Bernard R. Chaitman, Judith S. Hochman, David J. Maron, and Sean M. O’Brien; for the ISCHEMIA Research Group
‍
Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial

Gorav Batra, MD, PhD; Tatevik Ghukasyan Lakic, MSc; Johan Lindback, MSc; Claes Held, MD, PhD; Harvey D. White,MB ChB, DSc; Ralph A. H. Stewart, MD;Wolfgang Koenig, MD; Christopher P. Cannon, MD; Andrzej Budaj, MD, PhD; Emil Hagstrom, MD, PhD; Agneta Siegbahn, MD, PhD; Lars Wallentin, MD, PhD; for the STABILITY Investigators
‍
Interleukin 6 and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Chronic Coronary Syndrome

Gregory G. Schwartz, MD, PHD, Michael Szarek, PHD, Vera A. Bittner, MD, MSPH, Rafael Diaz, MD, Shaun G. Goodman, MD, J. Wouter Jukema, MD, PHD, Ulf Landmesser, MD, Patricio López-Jaramillo, MD, Garen Manvelian, MD,l Robert Pordy, MD,l Michel Scemama, MD, Peter R. Sinnaeve, MD, Harvey D. White, DSC, Ph Gabriel Steg, MD, for the ODYSSEY Outcomes Committees and Investigators
‍
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Stephen D.Wiviott, MD Robert P. Giugliano,MD, SM Marc S. Sabatine, MD, MPH, Harvey D. White, DSc, Philippe Gabriel Steg, MD Gregory G. Schwartz, MD, PhD
‍
Myocardial Infarction and Evolocumab

M. Olszowka, C. Held, N. Hadziosmanovic, S. Denchev, A. Manolis, L. Wallentin, H. D. White, R. A. H. Stewart, E. Hagstrom & the STABILITY Investigators
‍
Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome

Ralph A H Stewart, Peter Jones, Bridget Dicker, Yannan Jiang, Tony Smith, Andrew Swain, Andrew Kerr, Tony Scott, David Smyth, Anil Ranchord, John Edmond, Martin Than, Mark Webster, Harvey D White, Gerard Devlin
‍
High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial

Lars Wallentin, Niclas Eriksson, Maciej Olszowka, Tanja B. Grammer, Emil Hagstrom, Claes Held, Marcus E, Kleber, Wolfgang Koenig, Winfried Marz, Ralph A. H. Stewart, Harvey D. White, Mikael Aberg, Agneta Siegbahn
‍
Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

Harvey D. White
‍
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY

A. Bittner, MD, MSPH, Michael Szarek, PHD, Philip E. Aylward, BM, BCH, PHD, Deepak L. Bhatt, MD, MPH, Rafael Diaz, MD, Jay M. Edelberg, MD, PHD, Zlatko Fras, MD, Shaun G. Goodman, MD, Sigrun Halvorsen, MD, Corinne Hanotin, MD, Robert A. Harrington, MD, J. Wouter Jukema, MD, PHD, Virginie Loizeau, MS, Patrick M. Moriarty, MD, AngΦle Moryusef, MD, Robert Pordy, MD, Matthew T. Roe, MD, MHS, Peter Sinnaeve, MD, S
‍
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome Vera

Shaun G. Goodman, MD, MSc, Philippe Gabriel Steg, MD, Michael Szarek, PhD, Deepak L. Bhatt, MD, MPH, Vera A. Bittner, MD, MSPH, Rafael Diaz, MD, Robert A. Harrington, MD, J. Wouter Jukema, MD, PhD, Harvey D. White, DSc, Andreas M. Zeiher, MD, Gregory G. Schwartz, MD, PhD
‍
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES

Jean-Claude Tardif, MD, Marie-Pierre DubΘ, PhD, Marc A. Pfeffer, MD, PhD, David D. Waters, MD, Wolfgang Koenig, MD, PhD, Aldo P. Maggioni, MD, John J. V. McMurray, MB, ChB, Vincent Mooser, MD, Harvey D. White, DsC, Therese Heinonen, DVM, Donald M. Black, MD, and Marie-Claude Guertin, PhD
‍
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib

Bernard R. Chaitman, MD; Karen P. Alexander, MD; Derek D. Cyr, PhD; Jeffrey S. Berger, MD, MS.; Harmony R. Reynolds, MD; Sripal Bangalore, MD, MHA; William E. Boden, MD; Renato D. Lopes MD, PhD, MHS; Marcin Demkow, MD, PhD; Gian Piero Perna, MD; Robert K. Riezebos MD, PhD, Edward O. McFalls MD, PhD; Banerjee Subhash, MD; Akshay Bagai MD, MHS; Gilbert Gosselin, MD; Sean M. OÆBrien, PhD; Frank W. Rockhold, PhD; David D. Waters, MD; Kristian A. Thygesen, MD; Gregg W. Stone, MD; Harvey D. White, MD; David J.
‍
Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons

Mika Hilvo, PhD; Lars Wallentin, MD, PhD; Tatevik Ghukasyan Lakic, MSc; Claes Held, MD, PhD; Dimple Kauhanen, MSc; Antti JylhΣ, MSc; Johan LindbΣck, MSc; Agneta Siegbahn, MD, PhD; Christopher B. Granger, MD; Wolfgang Koenig, MD, PhD; Ralph A. H. Stewart, MD; Harvey White, MD; Reijo Laaksonen, MD, PhD; on behalf of the STABILITY Investigators
‍
Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.

Deepak L. Bhatt, MD, MPH, Andrew H. Briggs, DPHIL, Shelby D. Reed, PHD, Lieven Annemans, PHD, Michael Szarek, PHD, Vera A. Bittner, MD, MSPH, Rafael Diaz, MD, Shaun G. Goodman, MD, MSC, Robert A. Harrington, MD, Keiko Higuchi, MPH, Florence Joulain, MSC, J. Wouter Jukema, MD, PHD, Qian H. Li, SCD, Kenneth W. Mahaffey, MD, Robert J. Sanchez, PHD, Matthew T. Roe, MD, MHS, Renato D. Lopes, MD, PHD, Harvey D. White, DSC, Andreas M. Zeiher, MD, Gregory G. Schwartz, MD, PHD, Ph. Gabriel Steg, MD
‍
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes

Harvey D. White, DSc, Ralph A. H. Stewart, MD, Anthony J. Dalby, MB, ChB, Amanda Stebbins, MS, Christopher P. Cannon, MD, Andrzej Budaj, MD, PhD, Ales Linhart, MD, PhD, Prem Pais, MD, Rafael Diaz, MD, Philippe Gabriel Steg, MD, Sue Krug-Gourley, PhD, Christopher B. Granger, MD, Judith S. Hochman, MD, Wolfgang Koenig, MD, Robert A. Harrington, MD, Claes Held, MD, PhD, and Lars Wallentin, MD, PhD on behalf of the STABILITY Investigators
‍
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels b 70 mg/dL and glycosylated hemoglobin A1c b 7% are associated with lower major cardiovascular events

Chethan Kasargod, MBChBa, Gerry Devlin, MDb, Mildred Lee, MSca, Harvey D. White, DSc c, Andrew J. Kerr, MDa
‍
Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator

Michael Szarek, Vera A. Bittner, Philip Aylward, Marie Baccara-Dinet, Deepak L. Bhatt, Rafael Diaz, Zlatko Fras, Shaun G. Goodman, Sigrun Halvorsen, Robert A. Harrington, J.Wouter Jukema, Patrick M. Moriarty, Robert Pordy, Kausik K. Ray, Peter Sinnaeve, Sotirios Tsimikas, Robert Vogel, Harvey D.White, Doron Zahger, Andreas M. Zeiher, Ph. Gabriel Steg, and Gregory G. Schwartz
‍
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering

Stephen J. Nicholls, MBBS, PhD; A. Michael Lincoff, MD; Michelle Garcia, RN, BSN, CCRC; Dianna Bash, BSN; Christie M. Ballantyne, MD; Philip J. Barter, MBBS, PhD; Michael H. Davidson, MD; John J. P. Kastelein, MD, PhD; Wolfgang Koenig, MD; Darren K. McGuire,MD, MHSc; Dariush Mozaffarian, MD, DrPH; PaulMRidker, MD; Kausik K. Ray, MBChB, MD, MPhil; Brian G. Katona, PharmD; Anders Himmelmann, MD, PhD; Larrye E. Loss, PharmD, MBA; Martin Rensfeldt; Torbjorn Lundstrom, MD, PhD; Rahul Agrawal, MD; Venu Menon, M
‍
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk The STRENGTH Randomized Clinical Trial

Harvey D. White, DSc
‍
Research in the Antipodes at Green Lane

Harvey D. White, DSc
‍
Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?

Angela Pirillo and Alberico Luigi Catapano
‍
The cardiovascular benefit of Lp(a) reduction: not there yet

D.L. Bhatt, M. Szarek, P.G. Steg, C.P. Cannon, L.A. Leiter, D.K. McGuire, J.B. Lewis, M.C. Riddle, A.A. Voors, M. Metra, L.H. Lund, M. Komajda, J.M. Testani, C.S. Wilcox, P. Ponikowski, R.D. Lopes, S. Verma, P. Lapuerta, and B. Pitt, for the SOLOIST-WHF Trial Investigators
‍
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

2018-2015

2017

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson M, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL on behalf of the CHAMPION Investigators.

Cangrelor with and without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Pooled Analysis of Patient-Level Data from the CHAMPION PCI, PLATFORM, and PHOENIX Trials J Am Coll Cardiol 2017; 69(2):176-85

Omland T and White HD.

State-of-the-art: Biomarkers for risk stratification in patients with stable ischemic heart disease. An Expert Review for the annual special focussed issue of Clinical Chemistry. Clin Chem 2017; 63(1):165-176

Eisen A, Bonaca MP, Jarolim P, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KA, Bohula EA, Murphy SA, Braunwald E, Morrow DA.

High Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA2°P- TIMI 50 trial. Clin Chem.2017; 63(1): 307-315

Hagström E, Held C, Stewart RAH, Aylward PE, Budaji A, Cannon CP, Koenig W, Krug- Gourley S, Mohler ER, Steg PG, Tarka E, Ostlund O, White HD, Siegbahn A, Wallentin L.

Growth Differentiation Factor 15 Predicts All-cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem. 2017; 63(1):325-333

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson M, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL on behalf of the CHAMPION Investigators.

Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitiors – an exploratory analysis from the CHAMPION trials. Original Investigation.JAMA Cardiology. 2016;2(2): 127-135

Cornel JH, Ohman EM, Neely B, Jakubowski JA, Bhatt DL, White HD, Ardissino D, Fox KAA, Prabhakaran D, Armstrong PW, Tantry US, Erlinge D, Gurbel PA, Roe MT for the TRILOGY ACS Investigators.

Relationship of Platelet Reactivity with Bleeding Outcomes During Long-Term Treatment with Dual Antiplatelet Therapy for Medically Managed Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Insights from the TRILOGY ACS Trial. J Am Heart Assoc. 2017 Nov 4;5(11) pii: e003977

Sawlani NN, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris E, Mahaffey KW, White HD, Bhatt DL.

Impact of Cerebrovascular Events Older than One Year on Ischemic and Bleeding Outcomes with Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017;10:e004380. Doi: 10.1161

Leonardi S, MHS, Lopes RD, Steg PG, Abnousi F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, Stone GW, Gibson CM, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, and Mahaffey KW.

Implications of Different Criteria for Percutaneous Coronary Intervention-Related Myocardial Infarction on Study Results of Three Large Phase III Clinical Trials: The CHAMPION Experience. Eur Heart J Acute Cardiovasc Care. 2017; pii: 2048872616661692. [Epub ahead of print]

Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, Moliterno DJ, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf FV, Wallentin L, Strony J, Tricoci P.

Use of Thienopyridine Prior to Presentation for Non-ST-elevation Acute Coronary Syndromes and Association with Safety and Efficacy of Vorapaxar: Insights From the TRACER Trial. Eur Heart J Acute Cardiovasc Care. 2017; 6(2): 155-163

Roe MT, Clemmensen P, Hochman JS, Cyr DD, Neely ML, McGuire DK, Cornel JH, Huber K, Zamoryakhin D, White HD, Armstrong PW, Fox KA, Prabhakaran D, Ohman EM.

Long-term outcomes for women vs. men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TRILOGY ACS trial. J Am Heart Assoc; in press

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson M, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL on behalf of the CHAMPION Investigators.

Cangrelor is Associated with Similar Ischemic Risk but Lower Severe Bleeding Risk Compared with Clopidogrel and Routine Glycoprotein IIb/IIIa Inhibitors: A Propensity-Score Matched Analysis from the CHAMPION Trials. J Am Heart Assoc. 2017;

Goldstein SA, Newby LK, Cyr DD, Neely M, Luscher TF, Brown EB, Armstrong PW, Fox KAA, Prabhakaran D, White HD, EM Ohman, Roe MT, Hamm C.

Relationship between peak troponin values and Long-term ischemic events among Medically Managed Patients with Acute Coronary Syndromes. J of Am Heart Assoc. 2017; 6(4): doi:10.1161/JAHA.116.005334

Swinburn B, Vandevijvere S, Woodward A, Hornblow A, Richardson A, Burlingame B, Borman B, Taylor B, Breier B, Arroll B, Drummond B, Grant C, Bullen C, Wall C, Mhurchu CN, Cameron-Smith D, Menkes D, Murdoch D, Mangin D, Lennon D, Sarfati D, Sellman D, Rush E, Sopoaga F, Thomson G, Devlin G, Abel G, White H, Coad J, Hoek J, Connor J, Krebs J, Douwes J, Mann J, McCall J, Broughton J, Potter JD, Toop L, McCowan L, Signal L, Beckert L, Elwood M, Kruger M, Farella M, Baker M, Keall M, Skeaff M, Thomson M, Wilson N, Chandler N, Reid P, Priest P, Brunton P, Crampton P, Davis P, Gendall P, Howden-Chapman P, Taylor R, Edwards R, Beaglehole R, Doughty R, Scragg R, Gauld R, McGee R, Jackson R, Hughes R, Mulder R, Bonita R, Kruger R, Casswell S, Derrett S, Ameratunga S, Denny S, Hales S, Pullon S, Wells S, Cundy T, Blakely T.

Proposed new industry code on unhealthy food marketing to children and young people: will it make a difference? Viewpoint Article. N Engl J Med. 2017;130(1450): 94-101

Stewart RAH, Colquhoun DM, Marschner SL, Kirby AC, J Simes, Nestel PJ, Glozier N, O’Neil A, Oldenburg B, White HD, Tonkin AM on behalf of the LIPID Study Investigators.

Persistant psychological distress and mortality in patients with stable coronary artery disease. Heart. 2017: 103(23):1860-1866

Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Siegbahn A, Steg PG, Soffer J, Östlund O, Wallentin L on behalf of the STABILITY Investigators.

Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary artery disease – experiences from the STABILITY trial. J Am Heart Assoc. 2017;6(10): e005077 DOI: 10.1161/JAHA.116.005077

2016

White HD, Westerhout CM, Alexander KP, Roe MT, Winters KJ, Cyr DD, Fox KAA, Prabhakaran D, Hochman JS, Armstrong PW, Ohman EM.

Frailty is associated with worse long-term clinical outcomes in non-ST elevation acute coronary syndromes. Insights from the TaRgaeted platelet Inhibition to cLarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. Eur Heart J Acute Cardiovasc Care. 2016; 5(3):231-42

Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, Woodruffe S, Kerr A, Branagan M, Aylward PE, White HD (Advisory Board).

National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Heart, Lung and Circulation. 2016; 25(9): 895-951

Bagai A, Huang Z, Lokhnygina Y, Harrington RA, Armstrong PW, Strony J, White H, Leonardi S, Held C, Van de Werf F, Wallentin L, Tricoci P, Mahaffey KW.

Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. TRACER. Circ Cardiovasc Interv. 2016;8(6):e002314

Popma C, Sheng S, Korjian S, Daaboul Y, Chi G, Tricoci P, Huang Z, Moliterno D, White H, Van de Werf F, Harrington R, Wallentin L, Held C, Armstrong P, Aylward P, Strony J, Mahaffey K, Gibson CM.

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event: Committee in the Assessment of Stent Thrombosis: Results from the TRACER Angiographic Substudy. Circ Cardiovasc Interv. 2016; 9(5): e003114

Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson VM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL.

Variation in Patient Profiles and Outcomes in US and non-US Subgroups of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016;9:e003612

Kaul P, Ohman EM, Knight D, Anstrom KJ,Roe MT, Boden WE, Hochman JS, Gašparović V, Armstrong PW, McCollam P, Fakhouri W, Cowper P, Davidson-Ray L, Clapp-Channing N, White HD, Fox KAA, Prabhakaran D, Mark DB, for the TRILOGY ACS Investigators.

Health-related quality of life outcomes with prasugrel among medically managed non–ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2016;178:55-64

Déry JP, Mahaffey KW,Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV.

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheter Cardiovasc Interv. 2016;88(2): 163-73

Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD.

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016;178:176-84

Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Harrington RA, Alexander HJ, White HD, Van de Werf F,Piccini JP, Held C, Aylward PE, Moliterno DJ, Mahaffey KW, Tricoci P.

Sudden Cardiac Death after Non-ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiol. 2016; 1(1):73-9

Kerr AJ, Williams MJA, Harding S, White HD, Doughty RN, Nunn C, Devlin G, Grey C, Lee M, Flynn C, Rhodes M, Sutherland K, Wells S, Jackson RT, Stewart RAH, on behalf of the ANZACS-QI investigators.

The all New Zealand acute coronary syndrome quality improvement programme: implementation, methodology and cohorts (ANZACS-QI). N Z Med J. 2016; 129(1439):23-36

Steffel J, Giugliano RP, Braundwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.

Edoxaban versus warfarin in patients with atrial fibrillation and at increased risk of falling. An analysis from the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2016: 68(11): 1169-78

Adamo M, Ariotti S, Costa F, Curello S, Moschovitis A, de Vries T, White HD, Windecker S, Valgimigli M.

Phosphate-or Citrate-buffered Tirofiban versus unfractionated heparin and its impact on thrombocytopenia and clinical outcomes in patients with acute coronary syndrome. A post-hoc analysis from the PRISM trial. J Am Coll Cardiol: Cardiovas Interv. 2016;9(16):1667-76

Jackson LR, Piccini JP, Cyr DD, Roe MT, Neely ML, Martinez F, Luscher TF, Lopes RD, Winters KJ, White HD, Armstrong PW, Fox KAA, Prabhakran D, Bhatt DL, Ohman EM, Corbalan R, for the TRILOGY ACS Investigators.

Dual antiplatelet therapy and outcomes in patients with atrial fibrillation and acute coronary syndromes managed medically without revascularization: Insights from the TRILOGY ACS Trial. Clin Cardiol. 2016; 39(9):497-506]

Cavender M, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, and Harrington RA.

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. 2016; 134:723-733

Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM,Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL, on Behalf of the CHAMPION PHOENIX Investigators.

Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from CHAMPION PHOENIX. J Am Coll Cardiol Intv. 2016; 9(18): 1905-13

Petrie MC, Jhund PJ, She L, Adlbrecht C, Doenst T, Panza J, Hill J, Lee K, Rouleau J, Prior D, Ali I, Jyotsna M, Golba K, White HD, Carson P, Chrzanowski L, Romanov A, Miller A, Sopko G, Velazquez E.

Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016; 134:1314-24

Selvaraj S, Bhatt DL, Stone GW, Gibson CM, Steg PG, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, and Harrington RA, for the CHAMPION PHOENIX Investigators.

“Off-Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Finding from CHAMPION PHOENIX. Research Paper. J Am Coll Cardiol. 2016; 68(21):2385-7

Cholesterol Treatment Trialists’ (CTT) Collaboration incl White HD.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinal 2016; 4(10):829-39

2015

Roy A, Roe MT, Neely ML, Cyr DD, Zamoryakhin D, Fox KAA, White HD, Armstrong PW, Ohman EM, Prabhakaran D.

Impact of human development index on the profile and outcomes of acute coronary syndrome patients. Heart. 2015; 101: 279-285.

Wang TKM, Stewart RAH, Ramanathan T, Gamble G, White HD.

Post-operative aspartate aminotransferase levels independently predict mortality after isolated coronary artery bypass grafting. IJC Metabolic & Endocrine. 2015; 6: 31-35

Wong CK, Gao W, White HD.

ST deviations and serial changes after reperfusion therapy in patients with inferior STEMIs: Relationship between inferior leads, medial chest leads and lateral leads. Int J Cardiol. 2015; 184:348-249

Wong CK, Gao W, White HD, for the HERO-2 investigators.

Resolution of ST depression after fibrinolysis can be more important than resolution of ST elevation for many patients with inferior STEMIs. Int J Cardiol. 2015; 182:232–234.

White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Corese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA.

Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights from CHAMPION PHOENIX. JACC Cardiovasc Interv. 2015; 8(3):424-433

Vedin O, Hagstrom E, Gallup D, Neely M L, Stewart RA, Koenig W, Budaj A, Sritara P, Wallentin L, White H, Held C.

Periodontal disease in patients with chronic coronary heart disease: prevalence and association with cardiovascular risk factors. Eur J Prev Cardiol. 2015; 22(6):771-778

Choi J, Daly R, Lin G, Lahr BD, Wiste HJ, Beaver TM, Iacovoni A, Malinowski M, Friedrich I, Rouleau JL, Favaloro RF, Sopko G, Lang IM, White HD, Milano CA, Jones RH, Lee KL, Velazquez EJ, Oh JK.

Impact of surgical ventricular reconstruction on sphericity index in patients with ischemic cardiomyopathy: Follow-up from the STICH trial. Eur J Heart Failure 2015;17:453-463

Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA.

Glycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet Thrombin-Receptor Antagonist, among patients with non–ST-segment elevation acute coronary syndromes: Insights from the TRACER Trial. Am J Cardiol. 2015;115(10):1325-32

Ellis C, Hammett C, Ranasinghe I, Briffa T, Devlin G, Elliott J, Aliprandi-Costa B, Astley C, Redfern J, Howell T, Carr B, Lintern K, Lefkovitz J, Bloomer S, Matsis P, Hamer A, Williams M, Troughton R, Horsfall M, Hyun K, Gamble G, White H, French J, Brieger D, Chew D, for the Bi-National Acute Coronary Syndromes (ACS) ‘SNAPSHOT’ Audit Group.

A comparison of the management of acute coronary syndrome patients in Australia and New Zealand: Results from the Bi-National SNAPSHOT 2012 Audit. Intern Med J. 2015; 45(5):497-509

Wongpraparut N, Piyophirapong S, Maneesai A, Sribhen K, Krittayaphong R, Pongakasira R, White HD.

High-Sensitivity Cardiac Troponin T in Stable Patients Undergoing Pharmacological Stress Testing. Clin Cardiol. 2015; 38(5): 293-9

Warren J, Mehran R, Yu J, Xu K, Bertrand ME, Cox DA, Lincoff AM, Manoukian SV, Ohman EM, Pocock SJ, White HD, Stone GW.

Incidence and impact of totally occluded culprit arteries in patients presenting with non-ST-segment elevation myocardial infarction. Am J Cardiol. 2015; 115(4):428-33

Cholesterol Treatment Trialists’ (CTT) Collaboration [including White HD].

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174000 participants in 27 randomised trials Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2015; 385:1397-405

Cannon CP, Blazing MA, Giugliano RP et al for IMPROVE-IT Investigators including White HD.

Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97

AngiolilloDJ, Bhatt DL, StegG, StoneGW, WhiteHD, GibsonCM, HammCW, Price MJ, Prats J, Liu T, Mahaffey1 KW, Harrington RA.

Impact of Cangrelor Overdosing on Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention: Insights from the CHAMPION Trials. J Thromb Thrombolysis. 2015; 40(3): 317-22

Green JB, Bethel MA, Armstrong PW et al, for the TECOS Study Group including White HD.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 372:232-242

Bonow RO, Castelvecchio S, Panza JA, Berman DS, Velazquez EJ, Michler RE, She L, Holly TA, Desvigne-Nickens P, Kosevic D, Rajda M, Chrzanowski L, Deja M, Lee KL, White H, Oh JK, Doenst T, Hill JA, Rouleau JL, Menicanti L, for the STICH Trial Investigators.

Severity of remodeling, myocardial viability and survival in Ischemic LV dysfunction after surgical revascularization. JACC Cardiovasc Imaging. 2015;8(10):1121-9

Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke-Kaiser A, Hague W, Hunt D, Keech AC, Nestel P, Stewart R, Sullivan DR, Thompson PL, West M, White HD, Simes J, for the LIPID study Investigators.

Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: the LIPID biomarker study. Int J Cardiol. 2015; 201: 499-507

Clemmensen MD, Roe MT, Hochman JS, Cyr DD, Neely ML, McGuire DK, Cornel JH, Huber KM, Zamoryakhin D, White HD, Armstrong PW, Fox KAA, Prabhakaran D, Magnus Ohman E, for the TRILOGY ACS Investigators.

Long-term outcomes for women versus men with unstable angina/non–ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the TRILOGY ACS trial. American Heart Journal. 2015; 170(4):695-705

Padma K, Ohman EM, Knight JD, Anstrom K, Roe MT, Boden WE, Hochman JS, Gašparović V, Armstrong PW, McCollam P, Fakhouri W, Cowper P, Davidson-Ray L, Clapp-Channing N, White HD, Fox KAA, Prabhakaran D, and Mark DB for the TRILOGY ACS Investigators.

Health-related quality-of-life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the TRILOGY ACS trial. J Am Heart Assoc 2015; 170(4):683-694

Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM.

Concomitant proton pump inhibitor usem platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS study. Am Heart J. 2015;170(4):683-94

Kragholm K, Halim SA, Yang Q, Schulte P, Hochman JS, Melloni C, Mahaffey KW, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Ohman EM, Van de Werf F, Giugliano RP, Newby LK.

Sex-stratified Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Non-ST-segment Elevation Acute Coronary Syndrome Patients – Insights from Clinical Trials over 17 years. Circ Cardiovasc Qual Outcomes. 2015;8(4)357-67

Doll JA, Neely ML, Roe MT, Armstrong PW, White HD, Prabhakaran D, Winters KJ, Duvvuru S, Sundseth SS, Jakubowski JA, Gurbel PA, Ardissino D, Bhatt DL, Ohman EM, Fox KAA, for the TRILOGY ACS Investigators.

Impact of CYP2C19 Metabolizer status on Clinical Outcomes and Platelet Function of Medically Managed Acute Coronary Syndrome Patients Treated with Prasugrel vs. Clopidogrel. JACC 2015; 129(1428):10-16

Bohula May EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murhpy SA, Scirica BM, White HD, Braunwald E, Morrow, DA.

The efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with prior myocardial infarction and no history of stroke or TIA: Results from TRA 2°P-TIMI 50. Circulation. 2015; 132(20):1871-9

Van Diepen S, Tricoci P, Podder M, Westerhout C, Aylward P, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno D, White HD, Mahaffey K, Harrington R, Armstrong P.

Efficacy and safety of vorapaxar in non-ST –segment elevation ACS patients undergoing non-cardiac surgery. J Am Heart Assoc. 2015; 4(12):pii:e002546

Gutierrez JA, Harrington RA, Blankenship JC, Stone GW, Steg PG, Gibson CM,Hamm CW, Price MJ, Prats J, Deliargyris E, Mahaffey KW, White HD, Bhatt DL.

The Effect of Cangrelor and access site on ischaemic and Bleeding Events: Insights from CHAMPION PHOENIX. Eur Heart J. 2015;37:1122-1130

Vedin O, Hagström E, Budaj A, Denchev S, Harrington RA, Koenig W, Soffer J, Sritara P, Stebbins, Stewart R, Swart HP, Viigimaa M, Vinereanu D, Wallentin L, White HD, Held C.on behalf of the STABILITY Investigators.

Tooth loss is independently associated with poor outcomes in stable coronary heart disease. Eur J Prev Cardiol. 2015; pii: 2047487315621978 (epub ahead of press).

2014-2011

2014

De Ferrari GM, Fox KAA, White JA, Giugliano RP, Tricoci P, Reynolds HR, Hochman JS, Gibson CM, Theroux P, Harrington RA, Van de Werf F, White HD, Califf RM, Newby LK.

Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014; 3(1):37-45.

Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jenings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA.

Association of aspirin dose and vorapaxar safety and efficacy in patients with non–ST-segment elevation acute coronary syndrome from the TRACER Trial. Am J Cardiol 2014; 113 (6):936-44.

Genereux P, Stone G, Harrington R, Gibson M, Steg G, Angiolillo D, Price M, Prats J, Brener S, LasSalle L, Liu T, Todd M, Hamm C, Mahaffey K, White HD, Bhatt D.

Impact of intra-procedural stent thrombosis during percutaneous coronary Intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention) (CHAMPION) PHOENIX Trial. J Am Coll Cardiol. 2014;63(7):619-629.

Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW.

Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63(11):1048-1057. 133.

Mahaffey KW, Stevens SR, White HD, Nessel CC, Goodman SG, Piccini JP, Patel MR, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Califf RM, Fox KA, Breithardt G; ROCKET AF Investigators.

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35(4):233-41.

Alpert JS, Thygesen KA, White HD, Jaffe AS.

Diagnostic and therapeutic implications of type 2 myocardial infarction: Review and Commentary. Am J Med. 2014; 127:2:105-108

Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KAA, Califf RM, for the ROCKET AF Investigators.

Factors associated with major bleeding events: Insights from the ROCKET AF trial (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2014; 63(9): 891-900.

White HD, Thygesen K, Alpert JS, Jaffe AS.

Clinical implications of the Third Universal Definition of Myocardial Infarction. Heart. 2014; 100:424-432.

Meier P, Lansky AJ, Fahy M, Xu K, White HD, Bertrand ME, Mehran R, Stone GW.

The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial. Heart. 2014; 100(8):647-51.

Wang T, Li AY, Ramanathan T, Stewart RA, Gamble G, White HD.

Comparison of four risk scores for contemporary isolated coronary artery bypass grafting. Heart Lung Circ. 2014; 23(5):469–474.

Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD.

Impact of cardiovascular events on change in quality of life and utilities in patients after MI: A VALIANT Study. JACC Heart Failure. 2014; 2(2):159-65

White HD, Held C, Stewart RA, Tarka E, Brown R, Davies RY,Budaj A,Harrington RA, Steg G, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A Lonn E, López-Sendón J, Manolis AJ, Mohler III ER, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR,Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P,Sritara P,Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu JR, Cannon CP, Wallentin L, on behalf of the STABILITY Investigators.

Darapladib for prevention of ischemic events in stable coronary heart disease. N Engl J Med. 2014; 370:(18):1702-1711.

Lansky AJ, Ng VG, Meller S, Xu K, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW.

Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardovascuar Intervention. 2014;7:3:266-275.

Adlbrecht C, Huber K, Reynolds HR, Carvalho AC, Dzavik V, Steg PG, Liu L, Marino P, Pearte C, Rankin JM, White HD, Lamas GA, Hochman JS.

Effects of timing, location & definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. Int J Cardiol. 2014; 174(1):90-95.

Cornel JH, Ohman EM, Neely B, Clemmensen P, Sritara P, Zamoryakhin D, Armstrong PW, Prabhakaran D, White HD, Fox KA, Gurbel PA, Roe MT, for TRILOGY Investigators.

Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insight from the TRILOGY ACS Trial. Am Heart J. 2014;168(1):76-87.

White HD, Thygesen K, Alpert JS, Jaffe A.

Universal MI Definition update for cardiovascular disease. Curr Cardiol Rep. 2014; 16(6):492-502.

White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, David Hunt, Blankenberg S; LIPID Study Investigators.

Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: Results from the LIPID study. J Am Coll Cardiol. 2014; 63(4):345-354.

Vora AN, Chenier M, Schulte PJ, Goodman S, Peterson ED, Pieper K, Jolicoeur EM, Mahaffey KW, White HD, Wang TY.

Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2014; 168(2): 189-196.

Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, Stone GW.

Prognosis of patient with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: Propensity-matched analysis from the acute catheterization and urgent intervention triage strategy trial. Circ Cardiovasc Interv. 2014; 7:285-293.

Singh M, Stewart RA, White HD.

Implications of frailty in patients with cardiovascular disease. Eur Heart J. 2014; 35(26):1726-1731.

Funke-Kaiser A, Mann K, Biostat M, Colquhoun D, Zeller T, Hunt D, Simes J, Sullivan D, Sydow K, West M, White HD, Blankenberg S, Tonkin AM, on behalf of the LIPID Study Investigators.

Midregional prodrenomedullin and its changes predict recurrent major coronary events and heart failure in stable coronary heart disease: the LIPID study. Int J Cardiol. 2014; 172(2):411-48.

Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, Moliterno DJ, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW.

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: Results from the TRACER Trial. Eur Heart J: Acute Cardiovasc Care. 2014; 3(3):246-256.

Wang TK, Snow TA, Chen Y, Rostom H, White JM, Stewart JT, Webster MW, Ruygrok PN, Watson T, White HD.

High-sensitivity troponin level pre-catheterization predicts adverse cardiovascular outcomes after primary angioplasty for ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2014;3(2):118-125

Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M, for PROTECTION AMI Investigators.

Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: Results of the PROTECTION AMI randomized controlled trial. Eur Heart J. 2014; 35(37):2516-2523.

Stewart R, Szalewska D, She L, Lee K, Drazner M, Lubiszewska B, Hebeler R, Kosevic D, Ruengsakulrach P, Nicolau J, Coutu B, Choudhary S, Mark D, Cleland J, Pina I, Velazquez E, Rynkiewicz A, White HD.

Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass surgery or medical therapy: An analysis from the STICH (Surgical Treatment for Ischemic Heart Failure) trial. JACC Heart Fail. 2014; 2(4):335-343.

O’Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP.

Effect of darapladib on major coronary events after an acute coronary syndrome The SOLID-TIMI 52 randomised clinical trial. JAMA. 2014; 312(10):1006-1015; Erratum in: JAMA. 2014; 312(14):1473.

Benatar JR, Jones E, White HD, Stewart RAH.

A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factors. Eur J Prev Cardiol. 2014; 21(11):1376-1386.

Mueller M, Biener M, Vafaie M, Blankenberg S, White HD, Katus HA, Giannitsis E.

Prognostic performance of kinetic changes of high-sensitivity troponin T in acute coronary syndrome and in patients with increased troponin without acute coronary syndrome. Int J Cardiol. 2014; 174(3):524-529.

Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW.

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014;168(4):588-596.

Valgimigli M, Tricoci P, Huang Z, Aylward P, Armstrong P, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington R, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey K, Moliterno D.

Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014; 114(5):665-673.

White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW.

Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc. 2014; 3(4):e001032.

Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW.

Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). Am J Cardiol. 2014; 114(11):1638-1645.

Schwartz GG, Bessac L, Berdan LG, Bhatt D, Bittner V, Diaz R, Goodman S, Hanotin C, Harrington R, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe M, Tyrus Rorick T, Sasiela W, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White HD, Zeiher A, Steg PG.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndrome: Rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014; 168(5): 682-9.

Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward P, Moliterno D, Jennings L, White HD, Armstrong PW, Harrington RA, Strony J, Mahaffey KW.

Vorapaxar With or Without Clopidogrel after Non–ST-segment Elevation Acute Coronary Syndromes: Results from the TRACER Trial. Am Heart J. 2014; 168(6):869-877.

2013

Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, Moliterno DJ, Theroux P, Ohman EM, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA.

Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. Int J Cardiol. 2013; 167(2):548-54.

Vedin O, Hagström E, Stewart R, Brown R, Krug-Gourley S, Davies R, Wallentin L, White HD, Held C.

Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol. 2013;20(4):678-685.

2012

White HD, Reynolds HR, Carvalho AC, Pearte CA, Liu L, Martin CE, Knatterud GL, Džavík V, Kruk M, Steg PG, Cantor WJ, Menon V, Lamas GA, Hochman JS.

Reinfarction following PCI or medical management using the Universal Definition in patients with total occlusion after myocardial infarction: Results from Long Term Follow up of the OAT Cohort. Am Heart J. 2012; 163(4): 563-571.

Dangas GD, Mehran R, Xu K, Claessen BE, Fahy M, Parise H, Ohman EM, White HD, Stone GW.

Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovascular Interventions. 2012; 5(11):1097-1105.

Wong CK, Gao W, Stewart RAH, French JK, Aylward PEG, White HD for the HERO-2 Investigators.

The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction. . Eur Heart J. 2012; 33, 384–392.

Non ST-Elevation Acute Coronary Syndrome Guidelines Group and the New Zealand Branch of the Cardiac Society of Australia and New Zealand [Chairman: White HD].

New Zealand 2012 Guidelines for the Management of Non ST-Elevation Acute Coronary Syndromes. NZ Med J. 2012; 125(1357): 122-47.

Leonardi S, Mahaffey KW, White HD, Gibson CM, Stone GW, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON (CHAMPION) – PHOENIX trial. Am Heart J. 2012; 163(5): 768-776.

Latif M, Ellis C, Chataline A, Gamble G, Kyle C, White HD.

Availability of troponin testing for cardiac patients in New Zealand 2002 to 2011: Implications for patient care. NZ Med J. 2012; 125(1357): 4-20.

2011

Ambrosio G, Steinhubl S, Gresele P, Tritto I, Zuchi C, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Mehran R, Stone GW.

Impact of chronic antiplatelet therapy prior to hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: The ACUITY Trial. European Journal of Cardiovascular Prevention and Rehabilitation. 2011; 18(1): 1 121-128.

Mehta RH, O’Shea JC, Stebbins AL, Granger CB; Armstrong PW, White HD, Topol EJ, Califf RM, Ohman EM.

Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. J Am Coll Cardiol. 2011; 57(2): 138-146.

White HD.

Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. Am Heart J. 2011;161:450-61.

Wong CK. White HD.

Anticoagulant therapy in ST-segment elevation myocardial infarction. Expert Opinion on Pharmacotherapy. 2011; 12(2): 213-223.

Pegg TJ, Maunsell Z, Karamitsos TD, Taylor RP, James T, Francis JM, Taggart DP, White HD, Neubauer S, SelvanayagamJB.

Utility of cardiac biomarkers for the diagnosis of type V myocardial infarction post coronary artery bypass grafting: insights from serial cardiac magnetic resonance imaging. Heart. 2011; 97(10):810-816.

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White HD.

Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium (BARC). Circulation. 2011; 123(23):2736-2747.

Stewart RAH, White HD.

The role of lipoprotein associated phospholipase A2 as a marker and potential therapeutic target in atherosclerosis. Current Atherosclerosis Reports. 2011; 13(2):132-137.

2010-2006

2010

Mahaffey KW, Tonev ST, Spinler SA, Levine GN, Gallo R, Ducas J, Goodman SG, Antman EM, Becker RC, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ, Califf RM, on behalf of the SYNERGY Trial Investigators.

Obesity in patients with non–ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010; 139(2): 123-133.

Spinler SA, Gallup D, Levine DN, Ferguson JJ III, Rao SV, Gallo R, Ducas J, Goodman SG, Antman E, White HD, Biasucci L, Becker RC, Col JJ, Cohen M, Harrington RA, Califf RM, Mahaffey KW.

Relationship between renal function and outcomes in high-risk patients with non–ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010; 144(1): 36-41.

Tjandrawidjaja MC, Fu Y, Westerhout CM, White HD, Todaro TG, Van De Werf F, Mahaffey KW, Wagner GS, Granger CB, Armstrong PW, on behalf of the APEX-AMI Investigators.

Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. Eur Heart J. 2010; 31(5): 573-581.

Yan RT, Yan AT, Mahaffey KW, White HD, Pieper K, Sun JL, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG.

Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2010; 31(8): 958-966.

Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW.

Prognostic modelling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: Assessment from the ACUITY trial. Circulation. 2010; 121(1):43-51.

Lopes RD, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Mahaffey KW, Armstrong PW, Harrington RA, White HD, Wallentin L. Granger CB.

Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. American Journal of Medicine. 2010; 123: 134-140.

White HD, Aylward PE, Gallo R, Bode C, Steg G, Steinhubl SR, Montalescot G for the STEEPLE Investigators.

Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the STEEPLE trial. Am Heart J. 2010;159(1):110-116.

Califf RM, Armstrong PW, Granger CB, Harrington RA, Lee K, Simes RJ, Van de Werf F, Wallentin L, White HD; for the Virtual Coordinating Centre for Global Collaborative Cardiovascular Research (VIGOUR) organization.

Toward a new order in cardiovascular medicine: Re-engineering through global collaboration. Eur Heart J. 2010; 31(8): 911-917.

Bissessor N, Wee YS, Jayasinghe R, Zeng I, Lowe B, Kolbe J, Ellyet K, Kerr A, White H, Stewart R.

Complimentary roles for N-terminal pro-B-type natriuretic peptide and spirometry to assess functional capacity in patients with complex mixed heart valve disease. Kardiologia Polska. 2010; 68(1): 1-10.

Ohman EM, Roe MT, Armstrong PW, Fox KA, Prabhakaran D, White HD.

Public sensationalism and clinical trials: How to address the challenges of science? The American Journal of Medicine. 2010; 123(6): 481-483.

Jorapur V, Lamas GA, Sadowski Z, Reynolds H, Carvalho AC, Buller CE, Rankin J, Renkin J, Steg PG, White H, Vozzi C, Balcells E, Ragosta M, Martin CE, Srinivas V, Wharton W, Abramsky S, Mon AC, Kronsberg SS, Hochman JS.

Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction Insights from the Occluded Artery Trial. World J Cardiology. 2010; 2(1): 13-18.

Brown A, Tonkin A, White HD, Riddell T, Brieger D, Walsh W, Zeitz C, Jeremy R, Kritharides L.

The Cardiac Society Inaugural Cardiovascular Health Conference: conference findings and ways forward. Heart Lung Circ. 2010; 19(5-6): 264-268.

Kritharides L, Brown A, Brieger D, Riddell T, Zeitz C, Jeremy R, Tonkin A, Walsh W, White HD.

Recommendations arising from the inaugural CSANZ Conference on Indigenous Cardiovascular Health. Heart Lung Circ. 2010; 19(5-6): 269-272.

White HD, Walsh W, Brown A, Riddell T, Tonkin A, Jeremy R, Brieger D, Zeitz C, Kritharides L.

Rheumatic heart disease in Indigenous populations. Heart Lung and Circulation. 2010; 19(5-6): 273-281.

Kritharides L, Brown A, Brieger D, Riddell T, Zeitz C, Jeremy R, Tonkin A, Walsh W, White HD.

Overview and determinants of CV disease in indigenous populations. Heart Lung Circ. 2010; 19(5-6): 337-343.

Jeremy R, Tonkin A, White HD, Riddell T, Brieger D, Walsh W, Zeitz C, Brown A, Kritharides L.

Improving cardiovascular care for indigenous populations. Heart Lung Circ. 2010; 19(5-6): 344-350.

Brown A, Brieger D, Tonkin A, White HD, Walsh W, Riddell T, Zeitz C, Jeremy R, Kritharides L.

Coronary disease in indigenous populations: summary from the CSANZ indigenous Cardiovascular Health Conference. Heart Lung Circ. 2010; 19(5-6): 299-305.

Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJV, Califf RM, Velazquez EJ.

Atrial fibrillation management strategies after myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart. 2010; 96: 838-842.

Steg PG, Kerner A, Mancini GB, Reynolds HR, Carvalho AC, Fridrich V, White HD, Forman SA, Lamas GA, Hochman JS, Buller CE for the OAT Investigators.

Impact of collateral flow to the Occluded Infarct-Related Artery on clinical outcomes in patients with recent myocardial infarction: A report from the randomized Occluded Artery Trial. Circulation. 2010; 121: 2724-2732.

Wong CK, Gao W, Stewart RA, French JK, Aylward PE, Benatar J, White HD on behalf of the Hirulog and Early Reperfusion or Occlusion-2 (HERO-2) Investigators.

Prognostic value of lead V1 ST elevation during acute inferior myocardial infarction. Circulation. 2010; 122: 463-469.

Jones RH, White HD, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O’Connor CM, Rouleau JL.

Surgical Treatment for Ischemic Heart Failure (STICH) Trial Enrollment. J Am Coll Cardiol. 2010; 56: 490–498.

Wong CK, Gao W, Stewart RAH, Benatar J, French JK, Aylward PEG, White HD for the HERO-2 investigators.

aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction. Eur Heart J. 2010; 31(15):1845-1853.

Ellis C, Gamble G, Hamer A, Williams M, Matsis P, Elliott J, Devlin G, Richards M, White HD for the New Zealand Acute Coronary Syndromes [NZACS] Audit Group.

Patients admitted with an Acute Coronary Syndrome in New Zealand in 2007: Results of a second comprehensive nationwide audit and a comparison with the first audit from 2002. NZ Med J. 2010; 123(1319): 25-43.

Ellis C, Devlin G, Elliott J, Matsis P, Williams M, Gamble G, Hamer A, Richards M, White HD for the New Zealand Acute Coronary Syndromes [NZACS] Audit Group.

Acute Coronary Syndrome patients in New Zealand experience significant delays to access cardiac investigations and revascularisation treatment especially when admitted to non-interventional centres: Results of the 2nd comprehensive national audit of ACS patients in 2007. NZ Med J. 2010; 123(1319): 1-17.

Chin CT, Roe MT, Fox KAA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM on behalf of the TRILOGY ACS Steering Committee.

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) Trial. Am Heart J. 2010; 160 (1): 16-22.e1.

White HD.

Darapladib and its potential for plaque stabilization and prevention of cardiac events. Clinical Lipidology. 2010; 5(4): 465-476.

Morrow DA, Antman E, Fox K, White HD, Giugliano R, Murphy SA, McCabe CH, Braunwald E on behalf of the ExTRACT-TIMI 25 investigators.

One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. Eur Heart J. 2010; 31, 2097–2102.

Lansky AJ. Goto K, Cristea E, Fahy M, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Mehran R, Moses J, Leon M, Stone GW.

Clinical and Angiographic Predictors of Short and Long-Term Ischemic Events in Acute Coronary Syndromes: Results from The Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial. Circ Cardiovasc Interv. 2010; 3(4): 308-316.

Gladding P, MacKay J, Zeng I, Stewart RAH, Prabkahar R, Webster M, White HD.

A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. Personalized Medicine. 2010, 7(3): 319-325.

Gladding P, MacKay J, Webster M, White HD, Ellis K, Lee M, Kasabov N, Stewart RAH.

Longitudinal study of a 9p21.3 SNP using a national electronic healthcare database. Personalized Medicine. 2010, 7(4): 361-369.

Stewart RAH, Kerr AJ, Whalley GA, Legget ME, Zeng I, Williams MA, Lainchbury J, Hamer A, Doughty R, Richards MA, White HD for the New Zealand Heart Valve Study Investigators.

Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis. European Heart Journal. 2010; 31(18):2216-22.

White HD, Held C, Stewart RAH, Watson D, Harrington R, Budaj A, Steg G, Cannon C, Tarka E, Krug-Gourley S, Wittes J, Trivedi T, Wallentin L, on behalf of the STABILITY Steering Committee.

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with clinical coronary heart disease. Am Heart J. 2010; 160(4): 655-661.

Sleeper LA, Reynolds R, White HD, Webb J, Džavík V, Hochman JS.

A severity scoring system for risk assessment of patients with cardiogenic shock: A report from the SHOCK trial and registry. American Heart Journal. 2010; 160: 443-450.

Mehta SR, Tanguay JF, Jolly SS, Eikelboom JW, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani A, White HD, Chrolavicius S, Gao P, Fox KAA, Yusuf S on behalf of the CURRENT-OASIS 7 trial investigators.

Randomized comparisons of double versus standard dose clopidogrel and higher versus low dose aspirin in 17,263 individuals undergoing percutaneous coronary intervention for acute coronary syndromes. The Lancet. 2010; 376(9748): 1233-1243.

The CURRENT–OASIS 7 Investigators (including White HD).

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. N Engl J Med. 2010; 363: 930-942.

Simes JR, O’Connell RL, Aylward PE, Varshavsky S, Diaz R, Wilcox RG, Armstrong PW, Granger CB, French JK, Van de Werf FJ, Marschner IC, Califf RM, White HD for the HERO-2 Investigators.

Unexplained international differences in clinical outcomes after acute myocardial infarction following fibrinolytic therapy: lessons from the HERO-2 trial. Am Heart J. 2010; 159(6): 988-97.

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson M, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL on behalf of the CHAMPION Investigators.

Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitiors – an exploratory analysis from the CHAMPION trials. Original Investigation.JAMA Cardiology. 2016;2(2): 127-135

Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson M, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL on behalf of the CHAMPION Investigators.

Cangrelor is Associated with Similar Ischemic Risk but Lower Severe Bleeding Risk Compared with Clopidogrel and Routine Glycoprotein IIb/IIIa Inhibitors: A Propensity-Score Matched Analysis from the CHAMPION Trials. J Am Heart Assoc. 2017;

2009

White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Steinhubl S, Montalescot G.

The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the STEEPLE trial. Am Heart J. 2009; 157(1):125-131.

Menon V, Pearte CA, Buller CE, Steg GP, Forman SA, White HD, Marino PN, Katritsis DG, Caramori P, Lasevitch R, Loboz-Grudzien K, Zurakowski A, Lamas GA, Hochman JS.

Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: Insights from Occluded Artery Trial. Eur. Heart J. 2009; 30: 183-191.

Wong CK, Gao W, Stewart RAH, French JK, Aylward PEG, White HD for the HERO-2 investigators.

Relationship of QRS duration at baseline and changes over 60 minutes after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: Results from the HERO-2 trial. Heart. 2009; 95(4): 276-282.

Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW.

Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: The ACUITY Trial. Circulation. 2009; 119(5): 687-98.

White HD.

HORIZONS Trial: A step forward for primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy. 2009; 7(2):125-129.

Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV Jr, Hoekstra J, Gersh BJ, Phil D, Stone GW, Ohman EM.

Advanced age, antithrombotic strategy and bleeding in non-ST-Segment elevation acute coronary syndromes: Results from ACUITY. J Am Coll Cardiol. 2009; 53(12) 1021-1030.

Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, Gibson CM, Moliterno DJ, Van de Werf F, White HD, Harrington RA, Roe MT.

Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. Am Heart J. 2009; 157(4): 716-723.

Gallo R, Steinhubl SR, White HD, Montalescot G for the STEEPLE Investigators.

Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE Trial. Catheter Cardiovasc Interv. 2009; 73(3): 319-25.

Armstrong PW, Fu Y, Westerhout CM, Hudson MP, Mahaffey KW, White HD, Todaro TG, Adams PX, Aylward PEG, Granger CB.

Baseline Q surpasses time from symptom onset as a prognostic marker in STEMI patients treated with primary PCI. J Am Coll Cardiol. 2009; 53: 1503-1509.

White HD.

Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndromes. Expert Opinion on Drug Metabolism and Toxicology. 2009; 5: 529-538.

Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Phil D, Ohman EM, White HD, Moses JW, Lincoff AM, Ware JH, Stone GW.

Outcomes following preoperative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: The ACUITY Trial. J Am Coll Cardiol. 2009; 53:1965–72.

Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM.

Associations of Major Bleeding and Myocardial Infarction with the Incidence and Timing of Mortality in Patients Presenting with Non-ST-Elevation Acute Coronary Syndromes: A Risk Model from the ACUITY Trial. Eur Heart J. 2009; 30: 1457-1466.

Prasad A, Gersh BJ, Phil D, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Pocock SJ, McLaurin BT, Cox DA, Lansky AJ, Mehran R, Stone GW.

Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: An analysis from the ACUITY trial. J Am Coll Cardiol. 2009; 54: 477-486.

French JK, Harkness S, Sleeper L, Wong SC, Col J, Dzavik V, White HD, Hochman JS.

Cardiogenic SHOCK without flow-limiting angiographic coronary artery disease – (From The SHOCK Trial and Registry). Am J Cardiol. 2009; 104(1): 24-8.

Berger JS, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van de Werf F, Topol EJ, Harrington RA, Califf RM, Becker RC, Douglas PS.

Sex differences in mortality following acute coronary syndromes. JAMA. 2009; 302(8): 874-882.

Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E.

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38) Trial: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009; 119(21): 2758-2764.

Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJV.

Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: An Analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Eur Heart J. 2009; 30(12): 1450-1456.

Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJV, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD.

Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J. 2009; 30(18): 2226-2232.

Wong CK, White HD.

Cardiogenic shock from left ventricular dysfunction complicating an acute myocardial infarction. American Heart Hospital Journal. 2009; 7(1): 33-38.

Wong CK, White HD.

Bivalirudin in coronary angioplasty procedures. Hospital Pharmacy Europe. 2009; 44: 37-38.

Mehran H, Dangas GD, Kirtane A, Kim YH, Feit F, Manoukian S, Lansky AJ, Moses JW, Ebrahimi R, Ohman M, White HD, Pocock SJ, Stone GW.

Impact of chronic kidney disease on early (30 days), and late (one year) outcomes of patients with acute coronary syndromes: An ACUITY Substudy. JACC Cardiovascular Interventions. 2009; 2(8): 748-757.

Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB.

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009; 30(16):2019-2028.

Nikolsky E, Stone GW, Kirtane AJ, Lansky AJ, McLaurin B, Lincoff AM, Dangas GD, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME; Cox DA, Mehran R.

Gastrointestinal bleeding in patients with acute coronary syndromes: Incidence, predictors and clinical implications (Analysis from the ACUITY Trial). J Am Coll Cardiol. 2009; 54(14): 1293-1302.

Bissessor N, Stewart R, Wee YS, Zeng I, Jayasinghe R, Howes L, Kolbe J, Kerr A, Lowe B, Ellyett K, White HD.

Complex valve disease: Pre-surgical functional capacity evaluation using peak oxygen consumption. Journal of Heart Valve Disease. 2009; 18: 554-561.

Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW.

Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). Am J Cardiol. 2009; 103(9): 1196-1203.

Gladding P, White HD, Voss J, Ormiston J, Stewart J, Ruygrok P, Fu K, Baak R, White C, Webster M.

Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: A Dose Escalation Study. JACC Cardiovascular Interventions. 2009; 2(11):1095–1101.

Bhatt DL, Lincoff AM, Gibson M, Stone GW, McNulty S, Montalescot G, Kleiman N, Goodman S, White HD, Mahaffey KW, Pollack C, Manoukian S, Widimsky P, Chew D, Cura F, Manukov I, Tousek F, Jafar Z, Arneja J, Skerjanec S, Harrington RA on behalf of the CHAMPION PLATFORM Investigators.

Intravenous Platelet Blockade with Cangrelor during PCI. N Engl J Med. 2009; 361(24):2330-41.

Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman N, Goodman S, Amine M, Angiolillo D, Becker R, Chew D, French WJ, Leisch F, Parikh K, Skerjanec S, Bhatt DL.

Platelet Inhibition with Cangrelor in Patients Undergoing PCI. N Engl J Med. 2009; 361(24):2318-29.

Montalescot G, Gallo R, White HD, Cohen M, Steg G, Aylward PE, Bode C, Chiariello M, King III SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR for the STEEPLE Investigators.

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention: 1-year results from the STEEPLE trial. JACC Cardiovascular Interventions. 2009; 2(11):1083-91.

2008

White HD, Chew DP, Hoekstra JW, Pollack CV, Feit F, Lincoff AM, Bertrand ME, Pocock SJ, Ware J, Ohman EM, Mehran R, Stone GW.

Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non ST elevation acute coronary syndromes managed with an invasive strategy: Results from ACUITY. J Am Coll Cardiol. 2008;SI(18):1734-41 erratum in. J.Am.coll.cardiol 2008.; SI(22):2197

White HD, Chew D.

Acute Myocardial Infarction: the application of contemporary evidence. Lancet. 2008; 372: 570–84.

White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Manoukian SV, Landky AJ, Mehran R,. Moses JW, Stone GW.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: one year results from the randomized ACUITY trial. J Am Coll Cardiol. 2008; 52: 807-814.

Thygesen K, Alpert JS, Jaffe AS, White HD.

Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. Current Opinion Critical Care. 2008; 14: 543–548.

Alpert JS, Thygesen K, Jaffe A, White HD.

The universal definition of myocardial infarction: A consensus document. Heart. 2008; 94: 1335-1341.

To ACY, Looi KL, Damianovich D, Taylor GB, Sidebotham D, White HD.

A case of cardiogenic shock caused by capecitabine treatment. Nat Clin Pract Cardiovasc Med. 2008; 5(11):725-9.

Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams PX, Westerhout CM, White HD, Van ‘t Hof AWJ, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW.

ST-segment recovery after primary percutaneous coronary intervention for ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. Circulation. 2008; 118(5):1335-1346.

Kruk M, Kadziela J, Reynolds HR, Forman SA, Sadowski Z, Barton BA, Mark DB, Maggioni AP, Leor J, Webb JG, Kapeliovich M, Marin-Neto JA, White HD, Lamas GA, Hochman JS.

Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction. Results from the Occluded Artery Trial (OAT). JACC Cardiovascular Interventions. 2008; 1(5): 511-520.

Piccini JP, Hranitzky PM, Kilaru R, Rouleau JL, White HD, Aylward PE, Van de Werf F, Solomon SD, Califf RM, Velazquez.

Relation of mortality to failure to prescribe β-blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALIANT Registry). Am J Cardiol. 2008; 102(11): 1427-32.

Wong CK, White HD.

Drug evaluation: Enoxaparin. Aging Health. 2008; 4(6): 579-591.

Mehta S, Bassand JP, Chrolavicius S, Diaz R, Fox KAA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S on behalf of the CURRENT-OASIS 7 Steering Committee (White HD part of the Steering Committee).

Design and rationale of CURRENT-OASIS 7: A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2008;156(6): 1080-1088.

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P fort the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (including White HD).

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008; 372(9644): 1174-1183.

2007

Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran, Moses JW, for the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial Investigators.

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY PCI Trial. Lancet 2007;369:907-19.

Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Pollack CV Jr, Mehran R, White HD, for the ACUITY Investigators.

Prospective, randomized comparison of routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing Trial. JAMA. 2007;297(6):591-602.

White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW.

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results from SPORTIFF III and V. Arch Intern Med. 2007;167(3):239-245.

White HD, Braunwald E, Murphy SA, Jacob AJ, Gotcheva N, Polonetsky L, and Antman E.

Enoxaparin versus unfractioned heparin with fibrinolysis for ST elevation myocardial infarction in elderly and younger patients: Results from ExTRACT-TIMI 25. Eur Heart J. 2007;28(9):1066-71.

Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM.

Acute coronary care in the elderly, Part I: Non-ST-segment-elevation acute coronary syndromes: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation 2007. 115:2549-69.

Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM.

Acute coronary care in the elderly, Part II: ST-segment-elevation myocardial infarction: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. Circulation 2007. 115:2570-89.

Thygesen K, Alpert JS, White HD.

Joint ESC/ACCF//AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173-95.

Thygesen K, Alpert JS, White HD.

Joint ESC/ACCF//AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634-53.

Thygesen K, Alpert JS, White HD

Joint ESC/ACCF//AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28(20):2525-38.

2006

Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD; SHOCK Investigators.

Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295(21):2511-5.

Wong CK, Gao W, Raffel OC, French JK, Stewart RA, White HD.

Initial Q waves accompanying ST segment elevation at presentation of myocardial infarction independently predict higher 30-day mortality: Results from the HERO-2 trial. Lancet. 2006; 367 (9528): 2061-7.

White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PEG, Nessel CC, Ferguson JJ III, Califf RM.

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J; 2006; 152(6):1042-50.

Montalescot G, White HD, Gallo R, Cohen M, Steg G, Aylward PEG, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, for the STEEPLE Investigators.

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006: 355(10) 1006-17.

Wong CK, Gao W, Stewart RAH, Van Pelt N, French JK, Aylward PEG, White HD, and on behalf of the Hirulog Early Reperfusion Occlusion (HERO-2) Investigators.

Risk stratification of patients with acute anterior myocardial infarction and right bundle-branch block. Importance of QRS duration and early ST-segment resolution after fibrinolytic therapy. Circulation. 2006:114 783-89.

2005-2001

2005

Gersh BJ, Stone GW, White HD, Holmes DR Jr.

Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293:979-86.

White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, Wong CK, Stewart JT, Aylward PE, Wong SC, Hochman JS.

Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation. 2005;112:1992-2001.

White HD, Aylward PEG, Huang Z, Dalby AJ, Weaver WD, Swedberg KB, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJV, Califf RM, Pfeffer MA, on behalf of the VALIANT Investigators.

Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both following acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) trial. Circulation. 2005; 112:3391-9.

Szummer KE, Solomon SD, Velazquez EJ, Kilaru R, McMurray J, Rouleau JL, Mahaffey KW, Maggioni AP, Califf RM, Pfeffer MA, White HD, on behalf of the VALIANT Registry.

Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. Eur Heart J. 2005; 26(20): 2114-9.

2005

Armstrong PW, Newby LK, Granger CB, Lee KL, Simes RJ, Van de Werf F, White HD, Califf RM, for the Virtual Coordinating Centre for Global Collaborative Cardiovascular Research (VIGOUR) Group.

Lessons learned from a clinical trial. Circulation. 2004;110:3610-4.

Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD, for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators.

N-terminal pro–B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206-12.

White HD, Palmeri ST, Sleeper LA, French JK, Wong CK, Lowe AM, Crapo JW, Koller PT, Baran KW, Boland JL, Hochman JS, Wagner GS, on behalf of the SHOCK Trial Investigators.

Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK trial. Am Heart J. 2004;148:810-7.

2003

Williams BF, French JK, White HD, for the HERO-2 Consent Substudy Investigators.

Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet. 2003;361:918-22.

2000-1980

2000

Andrews J, Straznicky IT, French JK, Green CL, Maas ACP, Lund M, Krucoff MW, White HD, for the HERO-1 Investigators.

ST-segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation. 2000;101:2138-43.

1999

Hyde TA, French JK, Wong C-K, Straznicky IT, Whitlock RML, White HD.

Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression. Am J Cardiol. 1999;84:379-85.

North RA, Sadler L, Stewart AW, McCowan LME, Kerr AR, White HD.

Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation. 1999;99:2669-76.

1998

White HD, Van de Werf FJJ.

Clinical cardiology: new frontiers: thrombolysis for acute myocardial infarction. Circulation. 1998;97:1632-46.

White HD, Braunwald E.

Applying the open artery theory: use of predictive survival markers. Eur Heart J. 1998;19:1132-9.

The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators [chairman White HD].

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina [see comments]. N Engl J Med. 1998;338:1498-505. Comment in: N Engl J Med. 1998;338:1539-41.

1997

White HD, Aylward PE, Frey MJ, Adgey J, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B, on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 1997;96:2155-61.

1996

White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ, for the GUSTO-I investigators.

Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I Trial. Circulation. 1996;94:1826-33.

1995

White HD, Chew D.

Acute Myocardial Infarction: the application of contemporary evidence. Lancet. 2008; 372: 570–84.

Alpert JS, Thygesen K, Jaffe A, White HD.

The universal definition of myocardial infarction: A consensus document. Heart. 2008; 94: 1335-1341.

To ACY, Looi KL, Damianovich D, Taylor GB, Sidebotham D, White HD.

A case of cardiogenic shock caused by capecitabine treatment. Nat Clin Pract Cardiovasc Med. 2008; 5(11):725-9.

Wong CK, White HD.

Drug evaluation: Enoxaparin. Aging Health. 2008; 4(6): 579-591.

1994

White HD, Cross DB, Elliott JM, Norris RM, Yee TW.

Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994;89:61-7.

1993

White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, et al, for the investigators of the international tissue plasminogen activator/streptokinase study.

After correcting for worse baseline characteristics women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation. 1993;88:2097-103.

1989

White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Norris RM.

Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med. 1989;320:817-21.

1987

White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML.

Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.

White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock RML.

Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987;317:850-5.

OUR WORK

CLINICAL TRIALS

PUBLICATIONS

2023

2022-2019

2018-2015

2017

2014-2011

2014

2010-2006

2010

2009

2005-2001

2005

2005

2003

2000-1980

2000

1999

1998

1997

1996

1995

1994

1993

1989

1987

FIND US

CONTACT US

INFO